MX385122B - Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica. - Google Patents

Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.

Info

Publication number
MX385122B
MX385122B MX2016005294A MX2016005294A MX385122B MX 385122 B MX385122 B MX 385122B MX 2016005294 A MX2016005294 A MX 2016005294A MX 2016005294 A MX2016005294 A MX 2016005294A MX 385122 B MX385122 B MX 385122B
Authority
MX
Mexico
Prior art keywords
host disease
ibrutinib
treatment
chronic graft
graft
Prior art date
Application number
MX2016005294A
Other languages
English (en)
Spanish (es)
Other versions
MX2016005294A (es
Inventor
Amy Jo Johnson
David Miklos
Jason A Dubovsky
John C Byrd
Natarajan Muthusamy
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52993667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX385122(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2016005294A publication Critical patent/MX2016005294A/es
Publication of MX385122B publication Critical patent/MX385122B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2016005294A 2013-10-25 2014-10-24 Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica. MX385122B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361895981P 2013-10-25 2013-10-25
US201361910945P 2013-12-02 2013-12-02
US201461973176P 2014-03-31 2014-03-31
US201461973173P 2014-03-31 2014-03-31
PCT/US2014/062277 WO2015061751A1 (en) 2013-10-25 2014-10-24 Methods of treating and preventing graft versus host disease

Publications (2)

Publication Number Publication Date
MX2016005294A MX2016005294A (es) 2018-03-01
MX385122B true MX385122B (es) 2025-03-14

Family

ID=52993667

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005294A MX385122B (es) 2013-10-25 2014-10-24 Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
MX2021009400A MX392373B (es) 2013-10-25 2014-10-24 Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009400A MX392373B (es) 2013-10-25 2014-10-24 Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica

Country Status (14)

Country Link
US (7) US9795604B2 (enExample)
EP (2) EP3060218A4 (enExample)
JP (6) JP2016538270A (enExample)
KR (5) KR20250162912A (enExample)
CN (2) CN106102745B (enExample)
AU (5) AU2014339815B2 (enExample)
CA (2) CA3103411A1 (enExample)
EA (1) EA201690745A1 (enExample)
IL (2) IL245183B (enExample)
MX (2) MX385122B (enExample)
PH (2) PH12016500768B1 (enExample)
TW (1) TWI620565B (enExample)
WO (1) WO2015061751A1 (enExample)
ZA (1) ZA202208792B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
KR20150032340A (ko) 2012-07-24 2015-03-25 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
US9795604B2 (en) * 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
US20150157634A1 (en) * 2013-12-02 2015-06-11 Pharmacyclics, Inc. Methods of treating and preventing alloantibody driven chronic graft versus host disease
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
US10793566B2 (en) 2016-01-21 2020-10-06 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
EA201891626A1 (ru) * 2016-01-21 2019-04-30 Зибо Биополар Чангшенг Фармасьютикал Ко. Лтд. Ингибиторы тирозинкиназы брутона
CA3017567A1 (en) 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase
US20180185421A1 (en) * 2016-08-29 2018-07-05 Tokyo Metropolitan Government Composition comprising fecal microbiota
AU2018234827B2 (en) 2017-03-15 2024-04-04 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
US20220354629A1 (en) * 2018-01-09 2022-11-10 E2Bio Life Sciences, Llc Method and device for the enhancement of topical treatments for oral mucositis and other oral conditions
CN109481666B (zh) * 2018-12-21 2020-11-03 江苏省中医院 一种人体血液肿瘤pdx模型的建立方法
CN112439069A (zh) * 2019-08-28 2021-03-05 江苏恒瑞医药股份有限公司 一种vegfr抑制剂在制备治疗移植物抗宿主病的药物中的用途
US11433072B1 (en) 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
PT1212327E (pt) 1999-09-17 2004-01-30 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos
WO2001025238A2 (en) 1999-10-06 2001-04-12 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
JP2003516351A (ja) 1999-11-30 2003-05-13 パーカー ヒューズ インスティテュート コラーゲン誘導血小板凝集阻害剤
EP1246829A1 (en) 1999-12-17 2002-10-09 Ariad Pharmaceuticals, Inc. Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
WO2002038797A2 (en) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase, their identification and use
CA2436570A1 (en) 2000-12-06 2002-06-13 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
HUP0303538A2 (hu) 2000-12-21 2005-02-28 Bristol-Myers Squibb Co. Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
US20030124028A1 (en) 2001-08-10 2003-07-03 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
SE0202461D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0202462D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
MY144339A (en) 2003-09-08 2011-08-29 Aventis Pharma Inc Thienopyrazoles
US20050153990A1 (en) 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
US20050176792A1 (en) 2004-01-14 2005-08-11 Boehringer Ingelheim Pharmaceuticals, Inc. Ketone substituted benzimidazole compounds
CA2554551A1 (en) 2004-01-26 2005-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20050209284A1 (en) 2004-02-12 2005-09-22 Boehringer Ingelheim Pharmaceuticals, Inc. Tec kinase inhibitors
CA2581375A1 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
US8101770B2 (en) 2004-12-16 2012-01-24 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
WO2007016977A1 (de) 2005-08-05 2007-02-15 Delica Ag Vorrichtung zum extrahieren eines in einer kapsel enthaltenen extraktionsgutes mit einem flüssigen extraktionsmittel
WO2007027594A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
EP1957491A2 (en) 2005-11-12 2008-08-20 Boehringer Ingelheim International GmbH Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors
WO2007076228A2 (en) 2005-12-20 2007-07-05 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
AU2006336506B2 (en) * 2006-01-13 2012-06-28 Pharmacyclics Llc Inhibitors of tyrosine kinases and uses thereof
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
EP2526934B1 (en) * 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP5600063B2 (ja) 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
EP2361248B1 (en) 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2011017219A1 (en) 2009-08-03 2011-02-10 The Regents Of The University Of California Imidazoquinoxalinones and anti-tumor treatment
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
EP2717887B1 (en) * 2011-06-09 2017-12-27 University of Florida Research Foundation, Inc. Methods for treating or preventing graft versus host disease
US20130178483A1 (en) * 2011-06-28 2013-07-11 Pharmacyclics, Inc. Methods and Compositions for Inhibition of Bone Resorption
EP2771010A4 (en) * 2011-10-19 2015-04-01 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
HK1206624A1 (en) * 2012-04-11 2016-01-15 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
AU2013266069B2 (en) 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
US9658228B2 (en) * 2013-01-30 2017-05-23 The Board of Trustees of the Leland University Junior University Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
JP2016512549A (ja) * 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
AU2014251028A1 (en) * 2013-04-08 2015-11-05 Janssen Pharmaceutica Nv Ibrutinib combination therapy
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
US20150157634A1 (en) * 2013-12-02 2015-06-11 Pharmacyclics, Inc. Methods of treating and preventing alloantibody driven chronic graft versus host disease
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
PH12021550052A1 (en) 2022-02-14
CA3103411A1 (en) 2015-04-30
US9795604B2 (en) 2017-10-24
AU2014339815A1 (en) 2016-06-02
AU2023274176A1 (en) 2023-12-21
CN106102745A (zh) 2016-11-09
CN106102745B (zh) 2020-02-21
KR102357526B1 (ko) 2022-02-04
WO2015061751A1 (en) 2015-04-30
AU2022202686B2 (en) 2023-08-31
JP2024099527A (ja) 2024-07-25
JP6869400B2 (ja) 2021-05-12
MX2021009400A (es) 2022-05-17
US20250345335A1 (en) 2025-11-13
US20180078555A1 (en) 2018-03-22
JP2016538270A (ja) 2016-12-08
CN111265531B (zh) 2023-11-10
KR20220018079A (ko) 2022-02-14
KR20250162912A (ko) 2025-11-19
KR20230170797A (ko) 2023-12-19
JP7465305B2 (ja) 2024-04-10
JP2022133302A (ja) 2022-09-13
AU2025263907A1 (en) 2025-12-04
US10695350B2 (en) 2020-06-30
JP2020158512A (ja) 2020-10-01
EP3060218A1 (en) 2016-08-31
CA2928721A1 (en) 2015-04-30
PH12016500768A1 (en) 2016-06-20
EA201690745A1 (ru) 2016-11-30
KR20160068970A (ko) 2016-06-15
JP6712427B2 (ja) 2020-06-24
AU2014339815B2 (en) 2020-03-26
US20230097340A1 (en) 2023-03-30
AU2023274176B2 (en) 2025-12-04
TWI620565B (zh) 2018-04-11
US20150118209A1 (en) 2015-04-30
IL245183B (en) 2021-09-30
EP4115886A1 (en) 2023-01-11
CA2928721C (en) 2020-12-22
KR102452866B1 (ko) 2022-10-07
US20210121463A1 (en) 2021-04-29
KR102671643B1 (ko) 2024-05-31
US20240293408A1 (en) 2024-09-05
JP2019163274A (ja) 2019-09-26
MX2016005294A (es) 2018-03-01
US10463668B2 (en) 2019-11-05
IL285843A (en) 2021-09-30
PH12016500768B1 (en) 2016-06-20
EP3060218A4 (en) 2017-07-19
KR20220139452A (ko) 2022-10-14
TW201519893A (zh) 2015-06-01
MX392373B (es) 2025-03-24
ZA202208792B (en) 2023-12-20
CN111265531A (zh) 2020-06-12
AU2020204270A1 (en) 2020-07-16
US20200009148A1 (en) 2020-01-09
AU2022202686A1 (en) 2022-05-19
JP7090396B2 (ja) 2022-06-24
IL245183A0 (en) 2016-06-30
JP2021119145A (ja) 2021-08-12

Similar Documents

Publication Publication Date Title
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
CL2015002807A1 (es) Terapia de combinación
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX2016006955A (es) Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo.
MX2017011018A (es) Inhibicion de la actividad de olig2.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
MX391447B (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa